Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endotoxins | 9 | 2019 | 516 | 3.410 |
Why?
|
| Air Pollution, Indoor | 13 | 2022 | 931 | 2.430 |
Why?
|
| Asthma | 21 | 2022 | 6268 | 1.620 |
Why?
|
| Occupational Exposure | 8 | 2020 | 1806 | 1.610 |
Why?
|
| Lighting | 3 | 2023 | 211 | 1.380 |
Why?
|
| Schools | 15 | 2021 | 1495 | 1.370 |
Why?
|
| Textile Industry | 3 | 2015 | 74 | 1.320 |
Why?
|
| Cystic Fibrosis | 3 | 2024 | 1284 | 1.300 |
Why?
|
| Lung Diseases | 5 | 2022 | 1941 | 1.260 |
Why?
|
| Air Pollutants, Occupational | 4 | 2017 | 406 | 0.990 |
Why?
|
| Urban Population | 10 | 2020 | 2040 | 0.960 |
Why?
|
| Sputum | 2 | 2024 | 513 | 0.940 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 2 | 2022 | 57 | 0.920 |
Why?
|
| Environmental Exposure | 13 | 2022 | 4544 | 0.890 |
Why?
|
| Solar Energy | 1 | 2023 | 8 | 0.860 |
Why?
|
| Metagenomics | 2 | 2024 | 473 | 0.770 |
Why?
|
| Air Pollution | 3 | 2024 | 2380 | 0.700 |
Why?
|
| Hyperoxia | 1 | 2022 | 259 | 0.690 |
Why?
|
| Lung | 10 | 2024 | 10063 | 0.680 |
Why?
|
| Uganda | 6 | 2023 | 1353 | 0.680 |
Why?
|
| Pulmonary Infarction | 1 | 2019 | 10 | 0.680 |
Why?
|
| Tuberculosis | 2 | 2023 | 2010 | 0.670 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2019 | 25 | 0.670 |
Why?
|
| Dust | 5 | 2022 | 489 | 0.640 |
Why?
|
| Persian Gulf Syndrome | 1 | 2019 | 48 | 0.620 |
Why?
|
| Developing Countries | 2 | 2024 | 2914 | 0.600 |
Why?
|
| Chickens | 1 | 2020 | 842 | 0.590 |
Why?
|
| Occupational Diseases | 3 | 2016 | 1456 | 0.590 |
Why?
|
| Dermatitis, Atopic | 2 | 2023 | 724 | 0.590 |
Why?
|
| Kerosene | 1 | 2017 | 15 | 0.570 |
Why?
|
| Hypersensitivity | 3 | 2022 | 1168 | 0.570 |
Why?
|
| Food Hypersensitivity | 2 | 2022 | 734 | 0.560 |
Why?
|
| Nasal Mucosa | 2 | 2019 | 416 | 0.510 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 380 | 0.500 |
Why?
|
| Bacteria | 4 | 2024 | 2212 | 0.490 |
Why?
|
| Airway Remodeling | 1 | 2016 | 134 | 0.480 |
Why?
|
| Rural Population | 3 | 2020 | 2318 | 0.470 |
Why?
|
| Particulate Matter | 5 | 2022 | 2623 | 0.470 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 1043 | 0.460 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2013 | 3247 | 0.440 |
Why?
|
| Maxilla | 1 | 2016 | 486 | 0.430 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 1393 | 0.430 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 1065 | 0.410 |
Why?
|
| Protein C | 1 | 2012 | 134 | 0.400 |
Why?
|
| Mandible | 1 | 2016 | 746 | 0.380 |
Why?
|
| Anesthetics | 1 | 2016 | 525 | 0.360 |
Why?
|
| Allergens | 6 | 2022 | 1435 | 0.360 |
Why?
|
| Environmental Monitoring | 1 | 2017 | 1467 | 0.350 |
Why?
|
| Specimen Handling | 1 | 2015 | 704 | 0.350 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2009 | 42 | 0.330 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2024 | 755 | 0.320 |
Why?
|
| Metagenome | 2 | 2023 | 464 | 0.310 |
Why?
|
| Air Pollutants | 1 | 2022 | 2922 | 0.290 |
Why?
|
| Humans | 60 | 2025 | 766117 | 0.290 |
Why?
|
| Cooking | 2 | 2022 | 327 | 0.280 |
Why?
|
| Anemia | 1 | 2017 | 1514 | 0.280 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 4249 | 0.280 |
Why?
|
| Africa South of the Sahara | 2 | 2022 | 751 | 0.270 |
Why?
|
| Shock, Septic | 1 | 2012 | 771 | 0.260 |
Why?
|
| Inhalation Exposure | 2 | 2020 | 432 | 0.250 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2009 | 281 | 0.250 |
Why?
|
| Nitrogen Dioxide | 2 | 2020 | 538 | 0.250 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 2006 | 0.250 |
Why?
|
| China | 3 | 2016 | 2383 | 0.230 |
Why?
|
| Recovery of Function | 1 | 2015 | 2971 | 0.230 |
Why?
|
| Freezing | 1 | 2024 | 310 | 0.220 |
Why?
|
| Cotton Fiber | 2 | 2013 | 25 | 0.220 |
Why?
|
| Biomass | 1 | 2024 | 135 | 0.220 |
Why?
|
| Societies | 1 | 2024 | 106 | 0.220 |
Why?
|
| Female | 33 | 2024 | 396233 | 0.220 |
Why?
|
| Morbidity | 3 | 2020 | 1753 | 0.220 |
Why?
|
| Gene Expression | 2 | 2013 | 7582 | 0.210 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3684 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 2077 | 0.210 |
Why?
|
| Critical Care | 1 | 2016 | 2714 | 0.210 |
Why?
|
| Respiratory Tract Diseases | 2 | 2019 | 744 | 0.200 |
Why?
|
| Hypertension, Pulmonary | 1 | 2013 | 1604 | 0.200 |
Why?
|
| Respiratory Insufficiency | 4 | 2024 | 1241 | 0.190 |
Why?
|
| Embolism, Fat | 1 | 2021 | 46 | 0.190 |
Why?
|
| Sepsis | 2 | 2013 | 2603 | 0.190 |
Why?
|
| Rodent Control | 1 | 2021 | 15 | 0.190 |
Why?
|
| Respiratory Function Tests | 5 | 2017 | 1692 | 0.190 |
Why?
|
| Male | 30 | 2024 | 363935 | 0.190 |
Why?
|
| Prone Position | 1 | 2022 | 202 | 0.190 |
Why?
|
| Respiratory System | 1 | 2024 | 562 | 0.180 |
Why?
|
| Spores, Fungal | 2 | 2019 | 90 | 0.180 |
Why?
|
| Dendritic Cells | 1 | 2012 | 2747 | 0.180 |
Why?
|
| Eczema | 1 | 2023 | 244 | 0.170 |
Why?
|
| Oxygen | 2 | 2022 | 4247 | 0.170 |
Why?
|
| Child | 19 | 2023 | 80573 | 0.170 |
Why?
|
| Saliva | 1 | 2025 | 852 | 0.170 |
Why?
|
| Fungi | 3 | 2022 | 347 | 0.170 |
Why?
|
| Cryopreservation | 1 | 2024 | 727 | 0.160 |
Why?
|
| Housing | 3 | 2022 | 683 | 0.160 |
Why?
|
| HIV Seroprevalence | 1 | 2019 | 89 | 0.160 |
Why?
|
| Adult | 16 | 2024 | 223139 | 0.160 |
Why?
|
| Respiration, Artificial | 4 | 2024 | 2727 | 0.160 |
Why?
|
| Genomics | 1 | 2015 | 5926 | 0.160 |
Why?
|
| Alternaria | 1 | 2019 | 41 | 0.160 |
Why?
|
| HIV Infections | 2 | 2023 | 17535 | 0.160 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 14747 | 0.160 |
Why?
|
| Edema | 1 | 2022 | 763 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 812 | 0.150 |
Why?
|
| Family Characteristics | 1 | 2023 | 1001 | 0.150 |
Why?
|
| Animal Technicians | 1 | 2017 | 7 | 0.150 |
Why?
|
| Metals, Heavy | 1 | 2019 | 149 | 0.140 |
Why?
|
| Pest Control | 1 | 2017 | 29 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 1366 | 0.140 |
Why?
|
| Oxidants, Photochemical | 1 | 2017 | 77 | 0.140 |
Why?
|
| APACHE | 2 | 2020 | 268 | 0.140 |
Why?
|
| Neoplasms | 2 | 2016 | 22344 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2017 | 15808 | 0.130 |
Why?
|
| Urban Health | 1 | 2019 | 531 | 0.130 |
Why?
|
| Models, Theoretical | 3 | 2019 | 3561 | 0.130 |
Why?
|
| Administration, Inhalation | 2 | 2023 | 1154 | 0.130 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 560 | 0.130 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2015 | 39 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2020 | 572 | 0.120 |
Why?
|
| Soot | 1 | 2017 | 219 | 0.120 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 85 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 1362 | 0.120 |
Why?
|
| Textiles | 1 | 2015 | 43 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 1557 | 0.120 |
Why?
|
| Vehicle Emissions | 1 | 2019 | 651 | 0.120 |
Why?
|
| Mouth | 1 | 2017 | 383 | 0.120 |
Why?
|
| Critical Illness | 3 | 2024 | 2749 | 0.120 |
Why?
|
| Africa | 1 | 2017 | 726 | 0.120 |
Why?
|
| Antitubercular Agents | 1 | 2023 | 1380 | 0.120 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 1276 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2017 | 565 | 0.120 |
Why?
|
| Consensus | 1 | 2024 | 3202 | 0.110 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 12976 | 0.110 |
Why?
|
| Intensive Care Units | 3 | 2020 | 3798 | 0.110 |
Why?
|
| Smoking | 3 | 2016 | 9082 | 0.110 |
Why?
|
| School Health Services | 1 | 2017 | 388 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 4780 | 0.110 |
Why?
|
| Nose | 1 | 2017 | 519 | 0.110 |
Why?
|
| Carbon | 1 | 2017 | 673 | 0.110 |
Why?
|
| Boston | 2 | 2016 | 9335 | 0.100 |
Why?
|
| Brain Diseases | 1 | 2021 | 1552 | 0.100 |
Why?
|
| Workplace | 1 | 2019 | 873 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 1468 | 0.100 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 1476 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 10380 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 3665 | 0.100 |
Why?
|
| Publication Bias | 1 | 2012 | 157 | 0.100 |
Why?
|
| Airway Resistance | 1 | 2012 | 407 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2023 | 3112 | 0.090 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2012 | 300 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2022 | 81565 | 0.090 |
Why?
|
| Middle Aged | 10 | 2024 | 223083 | 0.090 |
Why?
|
| Alleles | 1 | 2022 | 6892 | 0.090 |
Why?
|
| Animals | 8 | 2023 | 168800 | 0.090 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1238 | 0.090 |
Why?
|
| Students | 2 | 2021 | 1741 | 0.080 |
Why?
|
| Multigene Family | 1 | 2013 | 1081 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2012 | 591 | 0.080 |
Why?
|
| Forced Expiratory Volume | 1 | 2015 | 1828 | 0.080 |
Why?
|
| Military Personnel | 1 | 2019 | 1260 | 0.080 |
Why?
|
| Patient Admission | 1 | 2017 | 1365 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 988 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5300 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2013 | 2270 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 1 | 2012 | 960 | 0.080 |
Why?
|
| Employment | 1 | 2015 | 1108 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 15882 | 0.080 |
Why?
|
| Skin | 2 | 2023 | 4482 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4649 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39243 | 0.070 |
Why?
|
| Mice | 6 | 2023 | 81839 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8525 | 0.070 |
Why?
|
| Genotype | 1 | 2022 | 13028 | 0.070 |
Why?
|
| Obesity | 2 | 2020 | 13085 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 8724 | 0.070 |
Why?
|
| Myeloid Cells | 1 | 2012 | 839 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2023 | 1588 | 0.070 |
Why?
|
| Hypotension | 1 | 2013 | 885 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2012 | 1181 | 0.070 |
Why?
|
| Inflammation | 3 | 2023 | 10860 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2009 | 344 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2019 | 54812 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2020 | 9354 | 0.060 |
Why?
|
| Models, Animal | 1 | 2012 | 2120 | 0.060 |
Why?
|
| Pneumonia, Viral | 2 | 2021 | 3233 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 2782 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 1852 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2019 | 4425 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2020 | 42511 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2015 | 1542 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 2213 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2009 | 1613 | 0.060 |
Why?
|
| Cysts | 1 | 2009 | 684 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2019 | 4857 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2009 | 630 | 0.060 |
Why?
|
| Patient Selection | 1 | 2016 | 4249 | 0.050 |
Why?
|
| Drainage | 1 | 2009 | 1182 | 0.050 |
Why?
|
| Aged | 7 | 2024 | 171219 | 0.050 |
Why?
|
| Risk Factors | 3 | 2016 | 74857 | 0.050 |
Why?
|
| Mass Screening | 1 | 2019 | 5450 | 0.050 |
Why?
|
| Quality of Life | 2 | 2022 | 13468 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 59868 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6493 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2012 | 4133 | 0.050 |
Why?
|
| Sterols | 1 | 2002 | 63 | 0.050 |
Why?
|
| Immunoglobulin E | 2 | 2020 | 1480 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2689 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2017 | 3283 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 1319 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 20700 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2009 | 1147 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2016 | 6254 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 11035 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3227 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 15403 | 0.050 |
Why?
|
| Rodenticides | 1 | 2021 | 21 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 15827 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2016 | 24276 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2023 | 388 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2012 | 3466 | 0.040 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2025 | 426 | 0.040 |
Why?
|
| Pneumonia | 1 | 2012 | 2159 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2016 | 8062 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2023 | 516 | 0.040 |
Why?
|
| Microfluidics | 1 | 2025 | 651 | 0.040 |
Why?
|
| Pruritus | 1 | 2023 | 376 | 0.040 |
Why?
|
| Neutrophils | 1 | 2012 | 3771 | 0.040 |
Why?
|
| Adolescent | 5 | 2020 | 88819 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2013 | 5340 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2023 | 1149 | 0.040 |
Why?
|
| Spirometry | 1 | 2022 | 929 | 0.040 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2025 | 789 | 0.040 |
Why?
|
| Air Microbiology | 1 | 2019 | 94 | 0.040 |
Why?
|
| Feces | 1 | 2025 | 1503 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2021 | 23605 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20137 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2021 | 455 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2023 | 1074 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2021 | 548 | 0.030 |
Why?
|
| Mites | 1 | 2017 | 46 | 0.030 |
Why?
|
| Macrophages | 1 | 2012 | 5776 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 9527 | 0.030 |
Why?
|
| Cytokines | 2 | 2023 | 7426 | 0.030 |
Why?
|
| Cities | 1 | 2019 | 542 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 208 | 0.030 |
Why?
|
| Cockroaches | 1 | 2017 | 92 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 59515 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 65219 | 0.030 |
Why?
|
| United States | 6 | 2020 | 72920 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 14066 | 0.030 |
Why?
|
| Viral Load | 1 | 2025 | 3386 | 0.030 |
Why?
|
| Cats | 1 | 2017 | 972 | 0.030 |
Why?
|
| Skin Tests | 1 | 2017 | 630 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2023 | 2142 | 0.030 |
Why?
|
| CpG Islands | 1 | 2019 | 1207 | 0.030 |
Why?
|
| Herpesvirus 2, Human | 1 | 2015 | 191 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1790 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 40108 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 22341 | 0.030 |
Why?
|
| Epigenomics | 1 | 2019 | 959 | 0.030 |
Why?
|
| Shock | 1 | 2015 | 316 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 326 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 1890 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2020 | 13046 | 0.020 |
Why?
|
| Health Services | 1 | 2017 | 756 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2002 | 2677 | 0.020 |
Why?
|
| Dogs | 1 | 2017 | 3824 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2015 | 1836 | 0.020 |
Why?
|
| Health Surveys | 1 | 2019 | 4058 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 9540 | 0.020 |
Why?
|
| Premature Birth | 1 | 2020 | 1830 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 1522 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 6059 | 0.020 |
Why?
|
| Prognosis | 2 | 2020 | 29912 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 3818 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10614 | 0.020 |
Why?
|
| Radiography | 1 | 2015 | 6943 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 5531 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2020 | 41684 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 9237 | 0.010 |
Why?
|
| Cholestadienols | 1 | 2002 | 5 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18386 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2021 | 6871 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18321 | 0.010 |
Why?
|
| Research Design | 1 | 2017 | 6206 | 0.010 |
Why?
|
| Rats | 1 | 2017 | 23717 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 1881 | 0.010 |
Why?
|
| Comorbidity | 1 | 2013 | 10579 | 0.010 |
Why?
|
| Brain | 1 | 2021 | 27177 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 3678 | 0.010 |
Why?
|
Concepts
(289)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(136)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_